Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariam Sameh Boshra has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Amany H. Hasanin

    Clinical Pharmacology Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt

    1 shared publication
  • Eman Kamal Habib

    Human Anatomy and Embryology Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt

    1 shared publication
  • Hebatalla Said Ali

    Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt

    1 shared publication
  • Hebatalla Said Ali

    Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, Egypt

    1 shared publication
  • Mahmoud Shawky El Meteini

    Department of General Surgery, The School of Medicine, University of Ain Shams, Cairo 11591, Egypt

    1 shared publication
  • Marwa Matboli

    Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt

    1 shared publication

Latest Publications

  • Open Access

    ZBiotics ameliorates T2DM-induced histopathological damage in liver, kidney and adipose tissues by modulating the NOD-like receptor signaling in Wistar rats

    by Mohammed Esawie, Marwa Matboli, Mariam Sameh Bushra, Amany H. Hasanin, Eman Kamal Habib, Reham Hussein Mohamed, Hebatalla Said Ali

    Probiotics serve as promising candidates in type 2 diabetes mellitus (T2DM) therapy. Not only they presumably reduce the T2DM prevalence, but also keep down its complications. In the present study, we explored the beneficial impact of ZBiotics, an engineered probiotic, on T2DM Wistar rats. In silico analysis was performed to construct a genetic-epigenetic network linked to STING-NOD pathway and autophagy signaling. Then, 30 Wistar rats were divided into 5 groups (each n = 6); normal group, diabetic model, B. subtilis, and ZBiotics treated rats at high and low doses. Experimental procedures were carried out including biochemical and histopathologic analyses. Samples were extracted from rats’ blood, liver, kidney and adipose tissues. At the molecular aspect, the molecular players, chosen by the in silico analysis, were assessed using 2–ΔΔCt to estimate their relative quantification. With immunohistochemistry, TNF-alpha and LC3B were assessed as reflectors for inflammation and autophagy respectively. ZBiotics was reported to ameliorate the T2DM-induced histological damage. Besides, it downregulated TNF-alpha and upregulated LC3B expression levels. At the biochemical aspect, ZBiotics corrected LDL-c and improved serum creatinine and CK-MB levels. Inflammation relevant genes have been downregulated regarding CHUK, NFKB1 and miR-611. Therefore, ZBiotics is speculated to operate by modulating the genetic-epigenetic network linked to inflammatory cGAS-STING and autophagy signaling. ZBiotics is recommended for clinical trials as a separate candidate or as an adjuvant to the conventional T2DM therapy.


  • Open Access

    Identification of a Multi-Messenger RNA Signature as Type 2 Diabetes Mellitus Candidate Genes Involved in Crosstalk between Inflammation and Insulin Resistance

    by Hebatalla Said Ali, Mariam Sameh Boshra, Sara H. A. Agwa, Mohamed S. Abdel Hakeem, Mahmoud Shawky El Meteini, Marwa Matboli

    Type 2 Diabetes Mellitus (T2DM) is a metabolic disease associated with inflammation widening the scope of immune-metabolism, linking the inflammation to insulin resistance and beta cell dysfunction. New potential and prognostic biomarkers are urgently required to identify individuals at high risk of β-cell dysfunction and pre-DM. The DNA-sensing stimulator of interferon genes (STING) is an important component of innate immune signaling that governs inflammation-mediated T2DM. NOD-like receptor (NLR) reduces STING-dependent innate immune activation in response to cyclic di-GMP and DNA viruses by impeding STING-TBK1 interaction. We proposed exploring novel blood-based mRNA signatures that are selective for components related to inflammatory, immune, and metabolic stress which may reveal the landscape of T2DM progression for diagnosing or treating patients in the pre-DM state. In this study, we used microarray data set to identify a group of differentially expressed mRNAs related to the cGAS/STING, NODlike receptor pathways (NLR) and T2DM. Then, we comparatively analyzed six mRNAs expression levels in healthy individuals, prediabetes (pre-DM) and T2DM patients by real-time PCR. The expressions of ZBP1, DDX58, NFKB1 and CHUK were significantly higher in the pre-DM group compared to either healthy control or T2DM patients. The expression of ZBP1 and NFKB1 mRNA could discriminate between good versus poor glycemic control groups. HSPA1B mRNA showed a significant difference in its expression regarding the insulin resistance. Linear regression analysis revealed that LDLc, HSPA1B and NFKB1 were significant variables for the prediction of pre-DM from the healthy control. Our study shed light on a new finding that addresses the role of ZBP1 and HSPA1B in the early prediction and progression of T2DM.